



Effective Date: 04-June-2025

EXEMPT REVIEW ASSESSMENT FORM

STUDY PROTOCOL INFORMATION

Reference Number	
WMSU REO code	
Study Protocol Title*	RxVision: OCR-Based Medical Prescription Reader using TroCR and BioBERT
Researcher*	Regine B. Bagalangit, Roland Jay J. Pada, Ushlie Mae U. Ungaya
Study Protocol Submission Date	

INSTRUCTIONS

To the Primary Reviewer:

Please evaluate how the exemption criteria outlined below apply to the study protocol by confirming the submitted information and putting your comments in the space provided under "REVIEWER COMMENTS." Finalize your review by indicating your conclusions under "RECOMMENDED ACTION" and signing in space provided for the primary reviewer.

	To be filled out by the Primary Reviewer				
CRITERIA FOR EXEMPTION	CRITERIA FOR EXEMPTION Indicate if the assessment point applies to the study protocol		the study	REVIEWER COMMENTS	
1. PROTOCOL ASSESSMENT		NO	Page & Line Number*		
1.1. Does this research involve human participants?					
1.2. Does this research involve use of non-identifiable human tissue/ biological samples?					
1.3. Does this research involve use of non-identifiable publicly available data? *Protocols that neither involve human participants, nor identifiable human tissue, biological samples and data shall					
be exempted from review (NEGRIHP 2017) 1.4. Does this research involve interaction with human					
participants?					
1.5. Type of research 1.5.1. Institutional quality assurance 1.5.2. Evaluation of public service program 1.5.3. Public health surveillance 1.5.4. Educational evaluation activities 1.5.5. Consumer acceptability test *These 5 have been identified in the NEGRIHP as exemptible, as long as it does not involve more than minimal risk.					

1.6. What is/are the method/s of data collection (please tick				
appropriate box)				
1.6.1. Surveys and/or questionnaire, Interviews, or				
observations of public behavior				
1.6.2. Audio/video recordings of public behavior				
1.6.3. Research which only uses existing data				
*These have been identified in the NEGRIHP as				
exemptible, as long as anonymity and/or confidentiality				
is maintained.				
1.7. Will the collected data be anonymized or de-identified?				
1.8. Is there a data protection plan?				
Measures or guarantees to protect privacy and				
confidentiality of participant information and in				
compliance with the Data Privacy Act of 2012 as				
indicated by data collection methods including data				
protection plans including the steps to be taken so that				
all who have access to the data and the identities of the				
respondents can safeguard privacy and confidentiality				
(ex. providing adequate instructions to research				
assistants, transcribers, or translators) (NEGRIHP				
2022); Plan on processing personal data, storage of				
data, access, disposal, and terms of use (NEGRIHP				
2022; Data Privacy Act of 2012)				
1.9. Is this research likely to involve any foreseeable risk				
of harm or discomfort to participants; above the level				
experienced in everyday life? (NEGRIHP 2022)				
*Please refer to section 2. Risk Assessment, prior to				
answering this item				
*If YES, then this protocol does not qualify for				
exemption				
2. RISK ASSESSMENT	YES	NO	Page & Line	
1.1. Does this research involve the following (please			Number	
select all that apply):				
1.1.1. Any vulnerable groups?				
1.1.2. Sensitive topics that may make participants				
feel uncomfortable (i.e. sexual behaviour, illegal				
,				
activities, racial biases, etc.)				
1.1.3. Use of drugs				
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1				
1.1.4. Invasive procedure (e.g. blood sampling) and				
specify				
specify 1.1.5. Physical stress/distress, discomfort				
specify 1.1.5. Physical stress/distress, discomfort 1.1.6. Psychological/mental stress/distress				
specify 1.1.5. Physical stress/distress, discomfort				
specify 1.1.5. Physical stress/distress, discomfort 1.1.6. Psychological/mental stress/distress				
specify 1.1.5. Physical stress/distress, discomfort 1.1.6. Psychological/mental stress/distress 1.1.7. Deception of/or withholding information from				
specify 1.1.5. Physical stress/distress, discomfort 1.1.6. Psychological/mental stress/distress 1.1.7. Deception of/or withholding information from subjects				
specify 1.1.5. Physical stress/distress, discomfort 1.1.6. Psychological/mental stress/distress 1.1.7. Deception of/or withholding information from subjects 1.1.8. Access to data by individuals or organizations				
specify 1.1.5. Physical stress/distress, discomfort 1.1.6. Psychological/mental stress/distress 1.1.7. Deception of/or withholding information from subjects 1.1.8. Access to data by individuals or organizations other than the investigators				

1.1.11. Is there any blood sampling involved	in the				
study?					
RECOMMENDED ACTION:					
☐ QUALIFIED FOR EXEMPTION					
QUALIFIED FOR EXEMITION					
☐ NOT QUALIFIED FOR EXEMPTION					
SUMMARY OF RECOMMENDATIONS:					
1.					
1.					
2.					
3.					
4.					
5.					
JUSTIFICATION FOR RECOMMENDED ACTION					
303111 ICATION FOR RECOMMENDED ACTION					
ERP CHAIR	Signature				
ERF CHAIR	Signature				
Data	Nones				
Date:	Name				
BEO Director	Cianatura				
REO Director	Signature				
Data	NI a mara a		VALD CA	AVEDDA DE D	
Date:	Name	ANAL	. YN D. SA	AVEDRA, Ph.D.,	J.D.